SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint
April 17, 2024 07:30 ET
|
Faruqi & Faruqi LLP
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Checkpoint Therapeutics, Inc. (“Checkpoint”...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, Checkpoint, and Sonder and Encourages Investors to Contact the Firm
April 16, 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm
April 16, 2024 13:50 ET
|
Schall Law
The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, and Checkpoint and Encourages Investors to Contact the Firm
April 12, 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, April 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint
April 12, 2024 10:20 ET
|
Faruqi & Faruqi LLP
NEW YORK, April 12, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Checkpoint Therapeutics, Inc. (“Checkpoint”...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm
April 10, 2024 15:02 ET
|
Schall Law
The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm
CHECKPOINT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Checkpoint Therapeutics, Inc. and Encourages Investors to Contact the Firm
April 08, 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against...
EvolveImmune Therapeutics Presents New Preclinical and Translational Data on Novel CD2 Costimulatory T Cell Engager Platform at 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
November 06, 2023 07:00 ET
|
EvolveImmune
BRANFORD, Conn., Nov. 06, 2023 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome the therapeutic...
EvolveImmune Therapeutics Enters into Strategic Research Collaboration with Kennedy Institute of Rheumatology
June 14, 2023 07:00 ET
|
EvolveImmune
BRANFORD, Conn., June 14, 2023 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome cancer-driven...
EvolveImmune Therapeutics Reports First Results from CRISPR-Cas9 T Cell Exhaustion Screening Platform at American Association for Cancer Research (AACR) Annual Meeting 2023
April 18, 2023 09:00 ET
|
EvolveImmune
Novel Technology Identified Genes that Promote T Cell Exhaustion, and which are Unique from PD-1/PD-L1 Checkpoint Pathway Engineered CAR-T Cells Lacking Exhaustion-Associated Genes Mediate Improved...